As the pharma industry steps up its search for stem cell-based therapies and regenerative medicines, Stem Cell Sciences (SCS) is uniquely positioned to meet the growth in demand for cells for research and drug discovery.
A trail-blazer in the field since 1994, SCS specialises in technologies to grow, differentiate and purify embryonic, neural and other tissue-specific stem cells. The pharma industry takes advantage of our patented technologies, proprietary cells, automated processes and services to accelerate their drug discovery programmes and regenerative medicine therapies.
Download our Fact Sheet.
SCS:
- Collaborates on developing methodologies and tools to turn stem cells into differentiated cells of interest
- Automates high volume production of stem cell lines
- Genetically modifies cells for population purification and sub-population identification
- Screens client compounds on stem and differentiated cells
- Provides proprietary cells and culture media
- Licenses SCS’s proprietary portfolio of stem cell technologies
- Fast tracks our customers’ use of stem cells
The Times Newspaper
December 26, 2008
‘Knockout’ rats are created to strike a blow against disease.
We manufacture and deliver:
- Physiologically relevant human cells
- Consistently and at scale
- Adult, foetal and embryonic stem and differentiated cells
We transfer knowledge and license our technologies
Demonstration of iPS technology – from brain to heart
NEW! Check out GS1-R™ and GS2-M™, our new rat ES and mouse iPS cell culture products.
Special introductory offer - For a limited time, save 20% on GS1-R™ and GS2-M™.
